PAI-1 in thrombosis and arteriosclerosis

Fibrinolysis and Proteolysis

Volumn 11, Issue SUPPL. 2, 1997, Pages 137-140

  Fujii, S ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTERIOSCLEROSIS; BLOOD CLOT LYSIS; CONFERENCE PAPER; DRUG EFFECT; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOSIS;

EID: 0030721553     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80087-2     Document Type: Conference Paper

References (39)

1. Reilly C F, Fujita T, Hutzelmann J E, Mayer E J, Shebuski R J. Plasminogen activator inhibitor I suppresses endogenous fibrinolysis in a canine model of pulmonary embolism. Circulation 1991; 84: 287-292.
2. Vaughan D E, Declerck P J, Van Houtte E, De Mol M, Collen D. (rPAI-1) effectively prevents thrombolysis in vivo. Thromb Haemostas 1992; 68: 60-63.
3. Biemond F J, Levi M, Coronel R, Janse M J, Ten Cate J W, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effect of a plasminogen activator inhibitor type 1 neutralizing monoclonal antibody. Circulation 1995; 91: 1175-1181.
4. Charlton p A, Faint R W, Bent F et al. A series of low molecular weight inhibitor (PAI-1) increase fibrinolysis and protect against thrombus formation in the rat. Thromb Haemostas 1995; 73: 1005 (abstract 404).
5. Carmeliet P, Collen D. Evaluation of the plasminogen/plasmin system in transgenic mice. Fibrinolysis 1994; 8 (Suppl. 1): 269-276.
6. Carmeliet P, Bouche A, Schoonjans L et al. Physiological consequences of loss of plasminogen activator gene function in mice, Nature 1994; 368: 419-424.
7. Carmeliet P, Bouche A, De Clercq C et al. Biological effects of disruption of the tissue-type plasminogen activator, urokinase type plasminogen activator and plasminogen activator inhibitor-1 gene in mice. Ann NY Acad Sci 1995; 748: 367-382.
8. Carmeliet P, Stassen J M, Schoonjans L et al. Plasminogen activator inhibitor 1 gene deficient mice. II. Effects on hemostasis thrombosis and thrombolysis. J Clin Invest 1993; 92: 2756-2760.
9. Reidy M A, Fingerele J, Lindner V. Factors controlling the development of arterial lesions after injury. Circulation 1992; 85 (Suppl. III): 43-46.
10. Jackson C L, Raines E W, Ross R, Reidy M A. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb 1993; 13: 1218-1226.
11. Vassalli J D. The urokinase receptor. Fibrinolysis 1994; 8 (Suppl. 1): 172-181.
12. Reuning U, Bang N U. Regulation of the urokinase type plasminogen activator receptor on vascular smooth muscle cell is under the control of thrombin and other mitogens. Arterioscler Thromb 1992; 12: 1161-1170.
13. Herbert J M, Lamarche I, Prabonnaud V, Dol F, Gauthier T. Tissue type plasminogen activator is a potent mitogen for human aortic smooth muscle cells. J Biol Chem 1994; 269: 3076-3080.
14. Sawa H, Fujii S, Sobel B E. Augmented arterial wall expression of type 1 plasminogen activator inhibitor induced by thrombosis. Arterioscler Thromb 1992; 12: 1507-1515.
15. Schneiderman J, Sawdey M S, Keeton M R et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
16. Chomiki N, Henry M, Alessi M C, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor 1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemostas 1994; 72:44-53.
17. Lupu F, Bergonzelli G E, Heim D A et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13: 1090-1100.
18. Lupu F, Heim D A, Bachmann F, Hurni M, Kakkar V V, Kruithof E K O. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 1444-1455.
19. Underwood M J, De Bono D P. Increased fibrinolytic activity in the intima of atheromatous coronary arteries: protection at a price. Cardiovasc Res 1993; 27: 882-885.
20. Padro T, Emeis J J, Steins M, Schmid K W, Kienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995; 15: 893-902.
21. Salomaa V, Stinson V, Kark J D, Folsom A R, Davis C E, Wu K K. Association of fibrinolytic parameters with early atherosclerosis, the ARIC Study. Circulation 1995; 91: 284-290.
22. Grobbee D E, Hoes A W, Koudstaal P J, Hofman A, Bots M L. Carotid intima-media thickness predicts myocardial infarction and stroke. The Rotterdam Study. Circulation 1996; 93: 630 (abstract).
23. Huber K, Jorg M, Probst P, Schuster E, Lang I, Kaindl F, Binder B R. A decrease in plasminogen activator inhibitor I activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemostas 1992; 67: 209-213.
24. Sakata K, Miura F, Sugino H et al. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 1996; 131: 1-6.
25. Kirschstein W, Simianer S, Dempfle C E, Keller H, Stegaru B, Rentrop P, Heene D L. Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty. Thromb Haemostas 1989; 62: 772-775.
26. Prinz M H, Harsh J. A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Amer Heart J 1991; 122: 545-551.
27. Juhan-Vague I, Alessi M C. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemostas 1993; 70: 138-143.
28. Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis: an update. Fibrinolysis 1994; 8: 253-262.
29. Rocha E, Paramo J A. The relationship between impaired fibrinolysis and coronary heart disease. A role for PAI-1. Fibrinolysis 1994; 8: 294-303.
30. Jansson J H, Nilsson T K, Olofsson B O. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12: 157-161.
31. Jansson J H, Olofsson B O, Nilsson T K. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88: 2030-2034.
32. Thompson S G, Kienast J, Pyke S D M, Haverkate F, Van de Loo J C W. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641.
33. Van de Loo J C W, Haverkate F, Thompson S G. Hemostatic factors and the risk of myocardial infarction. N Engl J Med 1995; 332: 389-390.
34. Cortellaro M, Cofrancesco E, Boschetti C et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb 1993; 13: 1412-1417.
35. Jansson J H, Nilsson T K, Johnson O. Von WiHebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Med J 1991; 66: 351-355.
36. Nishida M, Carley W W, Gerritsen M E, Ellingsen O, Kelly R A, Smith T W. Isolation and characterization of human and rat cardiac microvascular endothelial cells. Am J Physiol 1993; 264: H639-652.
37. Ito H, Okamura A, Iwakura K et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996; 93: 1993-1999.
38. Okada H, Lundgren C, Brown S L, Vinogradsky B, Wulfroth P, Fujii S. Effect of etofibrate and nicanartine on plasminogen activator inhibitor type-1 production in vitro by cultured vascular cells and on plasma plasminogen activator inhibitor type-1 activity in vivo in rabbits. Curr Ther Res 1996; 57: 192-202.
39. Sawa H, Sobel B E, Fujii S. Potentiation by hypercholesterolemia of the induction of aortic intramural synthesis of plasminogen activator inhibitor type 1 by endothelial injury. Circ Res 1993; 73: 671.